TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03847883

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Solution Ateplase
Description: Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Solution Ateplase
Description: Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Solution Ateplase
Description: Infusion Low dose 0.6 or 0.75 or 0.9 mg/kg Ateplase injection iv bolus 10% of total dose and infusion 90% of total dose in1 hour , with in 4.5Hr after onset of stroke
Study: NCT00565370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine, Cisplatin, Sorafenib
Description: Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine, Cisplatin, Sorafenib
Description: Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
Study: NCT02241967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4 Real sessions of Transcranial Direct Current Stimulation
Description: Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2 Real Sessions of Transcranial Direct Current Stimulation
Description: Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 2 real sessions of tDCS and 2 sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 1 Real Session of Transcranial Direct Current Stimulation
Description: Stimulation of brain areas associated with pain perception using low amplitude direct current of 2mA delivered by electrodes attached to the scalp. 1 real sessions of tDCS and 3 sham.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Direct Current Stimulation
Description: Four sessions of sham tDCS; control intervention.
Study: NCT05168241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: song/melodica group
Description: The patients who were divided into groups according to their wishes to sing or play the melodica were given warm-up training before the song group (20 min. warm-up training including breathing exercises, 20 min. singing) and melodica group (20 min. breathing). warm-up training including exercises, playing melodica for 20 minutes) was given with the researcher under the leadership of an experienced music teacher.~For two weeks, a total of 40 minutes of song/melodica training was given per week. The singing group was given an assignment to sing for at least 20 minutes a day and the melodica playing group to play the melodica for at least 20 minutes a day. The patients were asked to do their song/melodica homework for at least 20-30 minutes a day, and then they were told about the follow-up papers.~Patients in the song/melody group were followed up by telephone twice a total of 15 days at the 5th and 7th weeks.

Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: In the first interview, the pre-tests were applied by the researcher with the face-to-face interview technique. Afterwards, nursing education was given through the training guide prepared according to Pender's health promotion model. The control group was followed up and counseled by phone, twice a day, twice a day, in the 5th and 7th weeks.~Post-tests were applied at week 10 to evaluate the effectiveness of the interventions.
Study: NCT03833700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E7386
Description: E7386 doses.
Study: NCT01983241

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha-1 MP

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride for Injection, USP
Study: NCT03427294

Intervention type: OTHER
Intervention: Delphi study
Description: Delphi study on the optimal rehabilitation pathway following lumbar arthrodesis
Study: NCT02877004

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 3 Low-Level Laser Therapy Treatments Weekly
Description: Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2 Low-Level Laser Therapy Treatments Weekly
Description: Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 1 Low-Level Laser Therapy Treatment Weekly
Description: Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
Study: NCT04289441

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifiasthm
Description: Subjects will be instructed to take an active or placebo sachet twice daily for eight weeks, and subsequent intake of one dose daily for a further eight weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01380912

Intervention type: DRUG
Intervention: methylprednisoloneacetate
Description: Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
Study: NCT00762814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
Description: Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
Study: NCT00071487

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
Study: NCT03302559

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Facial cleanser
Description: Facial cleanser in the morning and in the evening.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Moisturizing lotion
Description: Fragrance free moisturizing lotion in the morning and in the evening.
Study: NCT00272337

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Dosage
Study: NCT03556917

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: iontophoresis + caffeine
Description: we will use cafeislaine c (caffeine) +galvanic current

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: iontophoresis + caffeine
Description: we will use cafeislaine c (caffeine) +galvanic current

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: iontophoresis + caffeine
Description: we will use cafeislaine c (caffeine) +galvanic current
Study: NCT03189264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous nephrolithotomy for kidney stones
Description: Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: percutaneous nephrolithotomy for kidney stones
Description: Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
Study: NCT04848350

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender essential oil
Description: Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lavender essential oil
Description: Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lavender essential oil
Description: Aromatherapy agents were added to the nebulizer at a rate of 2% (120 ml of water).The nebulizer was prepared and operated on in the SWL room before the procedure, The patients were taken to the room 5 minutes before the procedure and the nebulizer was operated on during the procedure
Study: NCT01724476

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folate with B12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT04132739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: The Nutrition Intervention will consider the participants' food preferences and concerns for managing glycemic control and maintaining muscle-mass. Each topic will be presented interactively and the participants will be encouraged to attend 2 times/week (attendance will be logged). The topics will be presented as a combination of evidenced-based materials for older adults with type 2 diabetes. We anticipate 3 sessions/topic during the 6-month intervention and will modify the topics and time to fit the needs of our audience. The lessons and materials will be offered in English and Spanish. The food quality change will be measured using a Food Frequency Questionnaire validated in Hispanic populations. The goals are to increase the participants' self-efficacy (belief and self-confidence) that they have the tools necessary to manage diabetes and reduce mobility impairments.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: The Exercise Intervention will involve 30-minute exercise sessions based on the Otago Exercise Program. The exercises involve lower and upper limb strengthening, balance training and a walking plan. The participants will receive illustrations of the exercises to do. Each participant will exercise for 30 minutes, 2x/week during supervised sessions in the facilities and be encouraged to do the exercises by themselves on days the group sessions are not offered. We will also teach self-monitoring for signs of low-blood glucose to ensure safety. Progression will be done every two weeks during the first 2 months, once at month 3, and once at month 6 by increasing intensity and/or difficulty and the walks by increasing continuous walking time and walking speed without compromising safety.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet and exercise
Description: A combination of the diet and exercise interventions following the same procedures previously described.
Study: NCT02346981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
Study: NCT04023630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rivaroxaban 15 MG Oral Tablet
Description: One 15 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 MG Oral Tablet
Description: One 15 mg tablet once daily for up to twelve months
Study: NCT00802048

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local anesthetic (Ropivacaine)
Description: Local anesthetic infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline serum infusion
Study: NCT02989220

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Reappraisal Coping Intervention
Study: NCT00071487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 1 mg/kg
Description: Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
Study: NCT04023630

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel 75 Mg Oral Tablet
Description: One 75 mg tablet once daily for up to twelve months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 MG Oral Tablet
Description: One 90 mg tablet twice daily for up to twelve months
Study: NCT00071487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 4 mg/kg
Description: Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 10 mg/kg
Description: Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
Study: NCT05154864

Intervention type: PROCEDURE
Intervention: SBUF-SMUF
Description: Intra-operative continuous ultrafiltration
Study: NCT02209350

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aorta-femoral bypass
Description: Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.~Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.~After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Recanalization and stenting of aorta-iliac segment
Description: Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.~Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapy: aspirin and clopidogrel
Description: prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Therapy: aspirin and clopidogrel
Description: prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
Study: NCT00710047

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: one single 10mg dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZD4054
Description: one single 10mg dose
Study: NCT04332705

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Cryptosporidium infection
Description: A biopsy or a surgical sample will be collected from every participant

Intervention type: DIAGNOSTIC_TEST
Intervention: Detection of Cryptosporidium infection
Description: A biopsy or a surgical sample will be collected from every participant
Study: NCT03044067

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pain neuroscience education + Exercise
Description: A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
Study: NCT03790176

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Infusion
Description: see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN

Intervention type: DRUG
Group type: OTHER
Intervention: Intravenous Infusion
Description: see arm/group description. NO INTERVENTION IN STUDY GROUP B! PATIENTS OF GROUP B WILL RECEIVE CAZ/AVI INDEPENDENTLY FROM STUDY PARTICIPATION BASED ON DECISION OF THEIR TREATING PHYSICIAN
Study: NCT03817905

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient navigator
Description: Intervention will utilize staff at the Seidman Cancer Center who are trained in patient navigation and have experience in navigating patients for breast cancer screening as well as sickle cell disease. The staff will undergo training for this study by study principal investigators which will include the target participant population, necessary steps in the navigation process and data that will be collected. In addition, they will receive brief training in supportive, listening technique. They will also be furnished with a telephone script for the initial participant contact.
Study: NCT03809013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48-ADC
Description: 2.0mg/kg IV every 2 weeks
Study: NCT00707174

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod Cream
Description: Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene Cream 0.1%
Description: Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
Study: NCT03724721

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: vacuum bottle
Description: using vacuum bottle plus catheter for drainage of pneumothorax
Study: NCT01005550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6 mg of ropivacaine
Description: 6 mg of ropivacaine are used for the spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 mg of ropivacaine
Description: 8 mg of ropivacaine are used for the spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg of ropivacaine
Description: 10 mg of ropivacaine for the spinal anaesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 mg of ropivacaine
Description: 12 mg of ropivacaine for the spinal anaesthesia
Study: NCT06010056

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine-Morphine
Description: PCA ketamine (Ketamine HCl, Pfizer Inc., US) 0.5 mg plus morphine 0.5 mg ml-1 (ratio 1:1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: PCA morphine (Pfizer Inc., US) 1 mg ml-1
Study: NCT00229450

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Estrogen
Description: 0.625 mg/day of conjugated Estrogen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogen
Description: 0.625 mg/day of conjugated Estrogen
Study: NCT00551486

Intervention type: PROCEDURE
Intervention: ultrasound-guided fine needle aspiration biopsy
Description: Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
Study: NCT02805374

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP1517
Description: Oral